University of Dundee

Splicing to Keep Cycling

Petasny, Mayra; Bentata, Mercedes; Pawellek, Andrea; Baker, Mai; Kay, Gillian; Salton, Maayan

Published in:
Trends in Genetics

DOI:
[10.1016/j.tig.2020.08.013](https://doi.org/10.1016/j.tig.2020.08.013)

Publication date:
2021

Licence:
CC BY-NC-ND

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Petasny, M., Bentata, M., Pawellek, A., Baker, M., Kay, G., & Salton, M. (2021). Splicing to Keep Cycling: The Importance of Pre-mRNA Splicing during the Cell Cycle. *Trends in Genetics*, 37(3), 266-278.
<https://doi.org/10.1016/j.tig.2020.08.013>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Splicing to keep cycling: The importance of pre-mRNA splicing during the cell cycle

Mayra Petasny¹, Mercedes Bentata¹, Andrea Pawellek², Mai Baker¹, Gillian Kay¹, Maayan Salton^{1*}

¹Department of Biochemistry and Molecular Biology, the Institute for Medical Research Israel Canada, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel;

²Centre for Gene Regulation and Expression, School of Life Sciences, University of Dundee, Dundee, United Kingdom

*To whom correspondence should be addressed. Tel: +972 26758814; Email: maayan.salton@mail.huji.ac.il, SaltonLab.com, @MaayanSalton.

Keywords: pre-mRNA splicing, cell cycle, alternative splicing, splicing factors, splicing regulation

Abstract

Pre-mRNA splicing is a fundamental process in mammalian gene expression and alternative splicing plays an extensive role in generating protein diversity. Since the majority of genes undergo pre-mRNA splicing, most cellular processes depend on proper spliceosome function. Here we focus on the cell cycle and describe its dependence on pre-mRNA splicing and accurate alternative splicing. We outline the key cell cycle factors and their known alternative splicing isoforms. We discuss different levels of pre-mRNA splicing regulation such as post-translational modifications and changes in expression of splicing factors. We describe the effect of chromatin dynamics on pre-mRNA splicing during the cell cycle. In addition, we focus on the spliceosome component SF3B1, which is mutated in many types of cancer, and describe the link of SF3B1 and its inhibitors to cell cycle.

Pre-mRNA splicing occurs in 97% of human genes. This suggests that most if not all cellular processes are dependent on the splicing machinery. Here we focus on the cell cycle process and discuss its many connections with pre-mRNA splicing. Splicing is regulated by both splicing factors and chromatin, which are known to alter during the cell cycle. We will review the changes in these two regulators and their effect on cell cycle.

Cell cycle

The cell-cycle process is highly conserved and precisely controlled to conduct genome replication. The process consists of four distinct phases, G0/G1, S (DNA synthesis), G2, and M (mitosis) with multiple checkpoints. These cell cycle checkpoints ensure reliable replication of the cell's DNA in the S phase and the exact division of the chromosomes into daughter cells. Ensuring that all chromosomes are aligned correctly on the mitotic spindle before division of the two daughter cells prevents dead, aneuploid, or mutant cells. The G1 and G2 phases serve as gaps between the S and M phases. G1 is the point where the decision is made whether to go into S phase and replicate the DNA or to exit the cell cycle and go to G0. G2 ensures full replication of the genome in S phase and the transition to cell division in M phase.

Cell cycle decisions are made by assessing both intra- and extracellular signals. Intracellular signals are proper replication of the DNA and the correct post-translational modification pattern of cell cycle proteins. Those proteins are cyclins and cyclin-dependent kinases (CDKs), which are a group of serine/threonine kinases. They form complexes with cyclins to stabilize, activate, and phosphorylate key cell cycle factors at specific phases [1]. CDKs' catalytic activities are regulated by interactions with cyclins and CDK inhibitors (CKIs). The formation of cyclin/CDK complexes controls the cell-cycle progression via phosphorylation of the target genes [2].

Epigenetic dynamics during cell-cycle progression

Chromatin binding proteins and chromatin modifications are dynamic during the cell cycle and chromatin impacts cell cycle events such as origin firing, chromosome segregation at mitosis and gene expression. Chromatin dynamics stem from histone modifiers which fluctuate in expression and post-translational modifications in a cell cycle-dependent manner [3]. For example, CDK1 and CDK2 can phosphorylate the chromatin factor, enhancer of zeste homolog 2 (EZH2), in a cell cycle-dependent manner and in turn silence genes during the cell cycle [4]. Chromatin also plays a large role in correct chromosome segregation by allowing chromosomes to condensate. This condensation is enabled by phosphorylation of H3 by the

Aurora B kinase that recruits the Condensin I complexes [5]. In addition, phosphorylation of H3 modulates the binding of repressive chromatin proteins to mitotic chromosomes [6].

Gene expression during cell-cycle progression

Many proteins that carry out important functions during the cell cycle display a cyclical expression pattern that is often regulated at the transcriptional level [7-9]. Thus, genes expressed in specific phases of the cell cycle are different from those expressed at steady-state [10]. Sensitive methods that identify small amounts of mRNA have identified specific transcripts expressed at each phase. These methods have also helped identify **enhancer RNA** (see Glossary) which indicates the specific enhancers activated during the cell cycle [10]. This adjusted expression requires a well-orchestrated regulation that also needs to adapt to the changing amount of DNA in the cell. This is made possible by regulation via chromatin structure. In addition to change in gene expression, M phase is considered to have less transcription and translation in general [11]. Interestingly cell-free lysates from mitotic cells are also less efficient in *in vitro* pre-mRNA splicing [11].

Pre-mRNA splicing

97% of human genes harbor introns which are removed in a process called pre-mRNA splicing [12]. The splicing reaction is catalyzed by the spliceosome, a multi-subunit complex, comprised of proteins and small noncoding RNAs (U1, U2, U4, U5 and U6) [13-15]. The spliceosome coordinates two transesterification reactions necessary to remove introns and to join the adjacent exons. It functions by step-wise formation of sub-complexes that recognize motif sequences on the pre-mRNA and promote efficient splicing [16].

Adjacent exons are not constitutively spliced together; alternative splicing is a process by which specific exons are selectively included or excluded [14]. Alternative splicing occurs in more than 90% of genes and allows for the production of multiple protein isoforms from a single pre-mRNA molecule by the use of splice sites [17-19]. Each isoform produced can harbor different functions and so alternative splicing contributes significantly to regulation of cellular function [20]. The main forms of alternative splicing are exon skipping, intron retention, alternative 3' splice site, alternative 5' splice site, and mutually exclusive exons [21]. In addition to protein diversity, alternative splicing can also lead to reduced translation of an mRNA by introduction of a toxic exon or intron which gives rise to a transcript with a premature stop codon that might undergo nonsense-mediated mRNA decay (NMD) or a transcript that will be sequestered in the nucleus [22].

Alternative splicing is frequently regulated by trans-acting factors binding to sequence motifs that are associated with the enhancing or silencing of pre-mRNA splicing. These motifs can be found in either exons or introns [13]. They are bound by an array of RNA-binding proteins that can be divided into two groups; the serine/arginine-rich proteins (SR proteins) and a heterogeneous group of nuclear ribonucleoproteins (hnRNPs) [23]. SR proteins harbor one or two RNA recognition motif (RRM) domains at the amino terminus that allow for RNA-binding specificity and a carboxy-terminal arginine/serine-rich (RS) domain affecting protein–protein interactions [24]. hnRNPs harbor the RRM domains and **unstructured domains** that could regulate their protein–protein interactions [25].

A major study of pre-mRNA splicing during cell cycle was conducted in human cervical cancer cells by RNA-seq analysis of synchronously dividing HeLa cells [26]. Dominguez *et al.* discovered 1182 genes whose gene expression was altered during the cell cycle and 1293 genes whose alternative splicing changed during the cell cycle and there was a minor overlap between these two groups [26]. This study suggested independent regulation of the two processes during cell cycle. Of all the genes expressed in the HeLa cells studied, 15% had periodic cell cycle-dependent alternative splicing. In addition to a major class of alternative splicing of cassette exons, sequencing RNA also pointed to intron retention as a key event regulated during cell cycle [26].

Since almost all genes undergo splicing it is reasonable to assume that cell cycle progression, or any other cell process, will be dependent on spliceosome function. Evidence that strengthens this assumption come from the results of multiple screens searching for novel cell cycle genes, such as those of Hwang *et al.* in yeast and Neumann *et al.* in HeLa cells [27, 28]. These screens led to the prediction that arrest is a general consequence of interfering with core spliceosome function; the genes revealed as cell cycle genes in these and further studies are *DHX8* [27], *PRPF8* [29, 30], *U2AF2* [31], *CDC5L* [32, 33], *DDX46* and *PRPF6* [34].

Since splicing is an essential process in mammalian cells, it can affect the ability of cells to proliferate by giving rise to a specific alternative spliced isoform [35] and the generation of specific splicing isoforms has recently been found to act as a driver of cancer [35-39] and can inhibit apoptosis (reviewed in [40]). In addition, global alterations in splicing arrays in cancer can be the result of changes in expression of splicing factors that may dictate an oncogenic splicing pattern [13–16], or by mutations that give rise to a specific splicing isoform with a potential to promote cancer [12]. In this review we focus on pre-mRNA splicing that affects the cell cycle directly and thus will not cover proliferation or apoptosis. An additional role for

some splicing factors is resolving **R loops**, generated between nascent transcripts and the DNA while transcription take place. Problems with R loop resolution lead to DNA damage and as a result halt cell cycle. This indirect effect of splicing factors on cell cycle is also not part of this review (reviewed in [41]). Many splicing factors have also been found to have additional functions in mitosis that do not involve pre-mRNA splicing (reviewed in [42]). Here we will focus on two main intersections between pre-mRNA splicing and cell cycle. The first is the need for pre-mRNA splicing to allow for production of key factors of the cell cycle that harbor introns. The second is alternative splicing of those key factors in order to produce the specific isoform needed for cell cycle progression. In addition, we will detail what is known to date about the role of splicing factors in the process that occur during the cell cycle. These splicing factors can be regulated in several ways: 1) by post-translational modifications; 2) at the level of their expression; 3) and via chromatin. We will review all of these different aspects here.

Pre-mRNA splicing of cell cycle key factors

Cell division cycle 25 (CDC25): Currently the only known targets of the members of the CDC25 family of phosphatases, CDC25A, B and C, are CDK/cyclin complexes [43, 44]. This function sets CDC25 as a regulator of all cell cycle stages, as its targets are CDK2/cyclin E at the G1–S transition and CDK1–cyclin B at the entry into mitosis [45]. Regulation of the CDC25 family was found to be at the protein level but also via alternative splicing [46-50]. Not much is known about the role of each of the alternative splicing isoforms or their regulation, but data exist on the change in phosphatase function [51] and differential protein stability between CDC25B isoforms [52]. In addition, U2AF1 was shown to be important for the pre-mRNA splicing of both CDC25B and C [53]. Andersen *et al.* identified Prp38 or Mfap1 as regulators of CDC25 (named mitotic phosphatase string) in *Drosophila* cells [54]. Depletion of PRP38 or MFAP1 led to arrest in G2/M, which might be a result of abnormal splicing of the CDC25.

Aurora kinase B (AURKB): AURKB is a member of the aurora kinase subfamily of serine/threonine kinases, part of the **chromosomal passenger complex (CPC)**, and is required for chromatin-induced microtubule stabilization and spindle assembly. While AURKB has several coding alternative splicing isoforms, their regulation during the cell cycle is not known. Lately it was suggested that an intron retention isoform with a premature termination codon is promoted during S/G2. As a result, nonsense-mediated decay of this isoform leads to reduced AURKB protein amount following M phase [26].

CDC-like kinase 1 (CLK1): CLK1's role as a kinase of splicing factors will be detailed in the next section. Alternative splicing regulation of CLK1 exon EB was shown to be important for its kinase activity [55, 56]. Inclusion of exon EB promotes a catalytically active CLK1. Interestingly CLK1 auto-regulates its alternative splicing, as the CLK1 isoform with exon EB promotes exon EB exclusion while the CLK1 isoform without exon EB promotes its inclusion [55, 56].

CDK2: CDK2 is a serine/threonine protein kinase, which has a role in all cell cycle phases. CDK2/cyclin E complex contributes to the phosphorylation of the retinoblastoma (RB) protein which drives the cell to S phase (Figure 1). In late S phase CDK2/cyclin A phosphorylates different targets to control the cell cycle transition from S to G2. For example, CDK2/cyclin A phosphorylates CDC6, an initiator of DNA replication. Phosphorylated CDC6 translocates to the cytoplasm to prevent re-replication of the DNA [57] (Figure 1). Regulation of CDK2 alternative splicing by exclusion of exon 5 represses CDK2 protein expression and thus impacts cell cycle control [58]. The regulation of CDK2 alternative splicing is coordinated by poly(rC) binding protein 1 and 2 (PCBP1/2) as well as the splicing factor PTB. PCBP1/2 and PTB promote CDK2 exon 5 inclusion by binding specifically to the C-rich polypyrimidine tract splice acceptor 5' to exon 5 [58] (Figure 1). Thus PCBP1/2 and PTB promote CDK2 protein stabilization.

Post-translational modifications of splicing factors during cell cycle

Post-translational modifications of splicing factors affect their protein–protein and protein–RNA interactions, intracellular localization, trafficking and activation, thus affecting pre-mRNA splicing as well as alternative splicing. Splicing factor kinases, such as SRSF protein kinase 1 (SRPK1) [59, 60], SRPK2 [61] and CLK1 [26], were shown to change in expression during the cell cycle to phosphorylate their targets in a way that is dependent on cell cycle phase.

Nuclear speckles provide storage for splicing factors with no or few post-translational modifications. Nuclear speckles break down and reform as cells progress through mitosis (Figure 2); this dynamic phenomenon was first shown to be dependent on SRPK1 in HeLa cells [59, 60, 62, 63] and later to be shared with its homologue SRPK2 in various human cells lines and tissues [61]. SRPKs are more active during M phase, leading to nuclear speckle disassembly by phosphorylating splicing factors [64]. Cell cycle-dependent phosphorylation of splicing factors by SRPK1 during M phase was first identified in HeLa cells by the use of a

radioactive isotope of phosphorus (^{32}P) [64]. SRSF1, SRSF2, SRSF3 and SRSF6 splicing factors were shown in HeLa cells to be phosphorylated by SRPK1, but the phosphorylation was not directly connected to cell-cycle regulation. At M phase exit there is reconstitution of the nuclear envelope, and most pre-mRNA splicing factors gradually self-organize to reform the nuclear speckle [62].

One of the first functions discovered for splicing factor phosphorylation during cell cycle was change in activity [11, 65]. SRSF10 serves as a splicing repressor in its unphosphorylated state, while in its phosphorylated state it is a sequence-specific splicing activator [66]. Although PP1 was demonstrated to dephosphorylate SRSF10 following heat shock, it is not known if it is the same phosphatase acting during cell cycle [67].

CLK1 expression level oscillates during the cell cycle promoting auto-phosphorylation that leads to its stabilization and peak expression at G2/M [26, 68]. CLK1's role as a splicing factor kinase [69, 70] is predicted to be the cause of its prominent regulation of alternative splicing during cell cycle and was found to be the central cause of most alternative splicing regulation [26]. Thus, silencing or inhibiting CLK1 leads to late S-phase/G2 phase arrest.

Phosphorylation of the splicing factor SRSF1 was shown in HeLa cells to regulate its function in pre-mRNA splicing [71] and to lead to a change in its subcellular localization in pediatric acute lymphoblastic leukemia cells [72]. In detail, phosphorylation on Tyr-19 by kinase TIE2 allowed cell cycle entry [72]. Furthermore mutating Tyr-19 resulted in cell-cycle arrest in the G0/G1 phase [72], while depleting DT40 cells of SRSF1 led to G2 cell cycle arrest [73]. The M-phase promoting factor, CDK1, phosphorylates SRSF1 on its RS domain on serines 227 and 238 in a cell cycle-dependent manner during G2/M phase [74], while this phosphorylation probably has merit in cell cycle regulation, it has never been demonstrated, nor has SRSF1 phosphorylation by SRPK2 [61, 75].

One of the major splicing factors studied in connection to cell cycle regulation is cell division cycle 5-like protein (CDC5L), also known as CDC5, which is part of the Prp19 complex, a component of the pre-mRNA splicing complex. CDC5L was shown to be essential for pre-mRNA splicing from yeast to humans [76-84]. Since *CDC5L* is expressed constitutively throughout the cell cycle [85], it was suggested that it is regulated via post-translational modification. Indeed it was shown that CDC5L is phosphorylated by CDK2 in a mitogen-dependent manner in monkey COS-7 cells and that its phosphorylation in murine RRC285 cells and human HeLa cells is critical to its association with the spliceosome [86, 87]. Furthermore,

it was found *in vitro* using rat liver nuclear extracts that phosphorylation of CDC5L by CDK2/cyclin E is required for CDC5L binding to the nuclear RNA binding protein, NIPPI1 [87] (Figure 1). Depletion of CDC5L causes dramatic mitotic arrest, chromosome misalignments and sustained activation of spindle assembly checkpoint [85, 88-90]. The mechanism can be inferred from data showing that CDC5L modulates the pre-mRNA splicing of a set of genes involved in mitosis [89]. One of these genes is α -*TUBULIN*, which can rescue CDC5L mutations by deleting its intron [91]. This suggests that CDC5L's role as a splicing regulator is needed for proper cell cycle regulation. However, recent evidence suggests that CDC5L has a direct role as a cell cycle component. CDC5L was shown in human HeLa and HCT-116 cells to bind the cell-cycle checkpoint kinase ataxia-telangiectasia and Rad3-related (ATR) and is important for the phosphorylation of its targets such as checkpoint kinase 1(CHK1), cell cycle checkpoint protein Rad 17 (RAD17) and Fanconi anaemia complementation group D2 protein (FANCD2) [92]. Blocking of replication fork in the latter study resulted in cell cycle arrest at the S phase, positioning phosphorylation by CDC5L as a regulator of S phase [92]. It could be that CDC5L regulates cell cycle via splicing regulation in the absence of DNA damage, and in addition has a direct role in cell cycle following DNA damage.

Interestingly the splicing factor CDC40's effect on cell cycle may also be rescued by intronless α -*TUBULIN*. *Saccharomyces cerevisiae CDC40* encodes a second-step pre-mRNA splicing factor with a role in cell division [93-97]. The transitions from G1/S and G2/M are regulated by *CDC40* as it participates in the splicing of key regulators of cell cycle such as α -*TUBULIN* [98] and *ANC1* [99]. Rescue of cell-cycle arrest in yeast was enabled by genomic replacement with an intronless form of these genes [98, 99].

Change in expression of splicing factors during the cell cycle

Differential expression of a splicing factor in a specific cell cycle phase can alter pre-mRNA splicing to allow for a proper cell cycle progression. Looking at all RNA binding proteins genome wide using RNA-seq, Dominguez *et al.* found 96 RNA binding proteins that oscillate during the cell cycle [26]. The RNA binding proteins were enriched for a function in pre-mRNA splicing and included the RS domain-containing factors SRSF2, SRSF8, TRA2A and SRSF6. These splicing factors were shown to change in expression but it is not clear how they directly regulate cell cycle.

An example of a splicing factor regulated in expression through a cell cycle-dependent manner is Wilms tumor 1-associating protein (WTAP). WTAP protein amount in human umbilical vein

endothelial cells (HUVECs) was found to be low in G1 and increased to reach its peak in G2/M. WTAP high expression in G2/M correlated with that of *CYCLIN A2* and it was shown in HUVECs to stabilize its mRNA through its 3' UTR sequence [100]. WTAP is localized throughout the nucleoplasm as well as in the nuclear speckles and partially colocalizes with splicing factors in HUVECs [101]. WTAP also binds to the RNA processing factors THRAP3 and BCLAF1 and this binding was shown to be critical to its localization to nuclear speckles [101]. Interestingly, THRAP3 and BCLAF1 regulate pre-mRNA splicing of genes involved in cell cycle regulation [102].

Another splicing factor with differential expression in cell cycle is RBM42 (TgRRM1) [103]. RBM42 was identified in the *Toxoplasma* parasite and its expression was found to be highest in late M and early G1. RBM42 binds the spliceosome components snRNA U4, U5 and U6 and is critical to the pre-mRNA splicing process. A point mutation in RBM42 in *Toxoplasma* led to G1 arrest with cell cycle regulation by RBM42 speculated to occur due to its role as a pre-mRNA splicing factor [103].

Chromatin alteration during cell cycle and its effect on alternative splicing

Recent evidence points to a contribution of epigenetic marks and higher order chromatin structure to alternative splicing regulation [104]. Moreover, genome-wide mapping has revealed enrichment of nucleosomes in exons [105, 106]. In addition, several histone modifications are enriched in exons relative to introns and numerous modifications, such as H3K36me3, are differentially associated with constitutive exons relative to alternative ones [107]. Since chromatin is dynamic during the cell cycle, it is possible that it serves as a regulator of alternative splicing.

The three histone modifications H3K36me3, H3K27ac, and H4K8ac mark alternatively spliced exons [108]. This was observed by following chromatin and alternative splicing states in human embryonic stem cells relative to differentiated cells. More than half of alternative splicing genes regulated by H3K36me3, H3K27ac, and H4K8ac are enriched for genes with function in G2/M cell-cycle phases [108]. Interestingly the effect of the histone modifications on alternative splicing was suggested to be mediated via transcription factors with a known role in cell differentiation [108].

A recent study identified the **histone demethylase** KDM3A as a regulator of alternative splicing during cell cycle [109]. RNA-seq following silencing of KDM3A revealed a group of genes with a role in cell cycle. Interestingly, KDM3A is a regulator of both transcription and

alternative splicing, but acting independently, as the expression and alternative splicing genes formed two separate groups. KDM3A was found to be necessary for the binding of the splicing factor SRSF3 to pre-mRNA. Silencing either KDM3A or SRSF3 promoted a higher percentage of cells in S-phase. Furthermore, this study indicated that alternative splicing of a target of KDM3A, the cell cycle gene *SAT1*, is the mediator between KDM3A and cell cycle regulation. Finally, these findings suggest that change in chromatin during the cell cycle can promote regulation of alternative splicing of genes important to this process.

SF3B1 and its splicing inhibitors role in cell cycle

The spliceosome component SF3B1 binds and stabilizes the **small nuclear RNA (snRNA)** U2. U2 binding to the branch point site is important for splice site recognition [110, 111]. The binding of the complex bulges out the adenosine at the branch point to facilitate the first catalytic reaction in the splicing cycle [112]. In addition, SF3B1 allows the identification of short exons flanked by long introns with differential GC content by binding to the exons' **nucleosomes** [113] (Figure 3). Both functions of SF3B1 rely on its phosphorylation at several sites. SF3B1 phosphorylation was also found to be cell cycle dependent. One SF3B1 kinase identified is dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A), which phosphorylates it on its Thr434 site [114, 115]. In addition, the G1 phase complex CDK2/cyclin E phosphorylates SF3B1 on Thr313 and this specific phosphorylation was shown to be critical for active splicing [116]. Many more possible phosphorylation sites are located mainly at its N terminal domain. Murthy *et al.* demonstrated cell cycle-dependent phosphorylation of SF3B1 [117]. This study suggested that nucleosome binding of SF3B1 is dynamic as a result of its phosphorylation and thus regulates alternative splicing of cell cycle genes. In detail, SF3B1 phosphorylation peaks at G2/M in a CDK1-dependent manner, and then decreases due to PP2A and PP1 phosphatase activities, as the cell progresses through G1/S [117] (Figure 3). Notably, SF3B1 binding to nucleosomes increases during G1/S when it has the lowest phosphorylation level. In a complementary manner, the interaction with nucleosomes is greatly diminished during G2/M, when the phosphorylation level is higher [117] (Figure 3).

The link of SF3B1 to cell cycle progression gained attention due to the elevated levels of **SF3B1** mutants in several types of cancers such as myelodysplastic syndrome (MDS), chronic lymphocytic leukemia, uveal and breast cancer [118-121]. How these mutations result in cancer is not yet fully understood. However, a few studies have shown that *SF3B1* mutations lead to the use of cryptic 3'-splice sites upstream of the canonical one and to the promotion of the selection of an alternative branch point [122-125]. Kesarwani *et al.* showed in human

transfected K562 cells and in cells derived from MDS patients, that these cryptic splice sites are detectable by the spliceosome because of a structural change that suffers upon the inclusion of a mutated SF3B1 subunit [126]. The effect of these events is an altered splicing pattern of a large list of genes related to cell cycle [127, 128]. In another study the disruption of SF3B1 induced a significant downregulation of pathways related to cell cycle regulation and led to G1 and G2 arrest in human MDS stem and progenitor cell lines (TF1, K562, HEL and SKM1) [129].

Huang *et al.* showed that the knockdown of SF3B1 in human erythropoietic cells caused early cell cycle arrest by the activation of the p53 pathway due to an isoform switch of E3 ligase makorin ring finger protein 1 (MKRN1) and downregulation of genes involved in mitosis and cytokinesis [130]. In loss-of-function zebrafish mutants, erythrocytes also presented with G0/G1 arrest [131]. Here, SF3B1's effect was suggested to cause elevated expression of transforming growth factor β (TGF β) and decreased expression of cell cycle genes [131].

A significant tool to study the role of SF3B1 in cell cycle are its many inhibitors (reviewed in [132]). All SF3B1 inhibitors studied have demonstrated anti-tumoral properties [110, 133-136] and a common pharmacophore model by which their specific interaction with SF3B1 provokes a conformational change and leads to splicing alteration due to a branch point recognition disturbance [111, 132, 137]. The fact that cells with SF3B1 inhibition or downregulation leads to similar aberrant splicing patterns suggest that affected genes share similarities at the 3' splice site and weak branch point sites [126-128, 132]. Interestingly each of the SF3B1 inhibitors can have a different effect on cell cycle [138]. Pladienolide B can lead to early (G1) as well as late (G2/M) arrest in two erythroleukemia cell lines, HEL and K562 [139], while isoginkgetin provokes slowdown of multiple phases in the cell cycle (G1, S and G2) but not M phase in human colon HCT116 cells and ovarian cancer A2780 cells [140]. A detailed investigation of the effect of spliceostatin A found reduced cell proliferation in HeLa cells due to decreased expression of cell cycle genes such as *CYCLIN A2* and *AURORA A KINASE* [111]. The mechanism that leads to the change in expression was suggested to be mediated by nonproductive pre-mRNA splicing. In a study using four types of human cells, HeLa, Rh18, HEK293 and primary fibroblasts, it was found that Sudemycin E inhibits SF3B1 binding to nucleosomes. Diminished H3K36me3 mark in these nucleosomes was also detected and cell cycle arrest was observed (G2 phase) [141]. We have described here various cell cycle alterations by SF3B1; these diverse and sometimes contradicting effects might stem from its differential expression in different cell types with diverse genetic backgrounds [142, 143].

Concluding Remarks

There is an increasing awareness of the importance and potential of pre-mRNA splicing in disease and therapy. Furthermore, alternative splicing is of great physiological relevance as it enables the production of multiple protein isoforms from a single pre-mRNA molecule by the combinatorial use of splice sites. The various protein isoforms produced can have different functions and as such alternative splicing contributes significantly to regulation of cellular function. Here we focus on the novel, and very exciting, insights into the emerging field of splicing modulation during the cell cycle.

The exact splicing patterns in each of the cell cycle phases is yet to be rigorously characterized. In the future combining this data with the different levels of alternative splicing regulation described here, namely splicing factor expression; post-translational modification and chromatin dynamics, can set the path to a deeper understanding of alternative splicing regulation in cell cycle and beyond (see Outstanding Questions box).

Figure Legends

Figure 1: Alternative splicing of CDK2 is regulated in order to phosphorylate splicing factors important for cell cycle progression. A. PCBP1/2 and PTB bind the 5' splice site of CDK2 exon 5 (dark red rectangle) to promote its inclusion. CDK2 exon 5 inclusion gives rise to a more stable protein serving as a more potent kinase. B. The CDK2/cyclin E complex phosphorylates retinoblastoma (RB) protein to drive the cell to S phase. In late S phase CDK2/cyclin A phosphorylates CDC6 to allow for exit from S phase. Finally CDK2/cyclin E phosphorylates the splicing factor CDC5L, which regulates the splicing of many genes involved in cell cycle.

Figure 2: Nuclear speckles are stable during interphase and disperse during early metaphase. Cellular localization of the nuclear speckle marker SRSF2 in HeLa cells at different cell cycle stages. Arrow heads denote splicing speckles. Scale bar 6.5 μ m.

Figure 3: The spliceosome component SF3B1 is essential for cell cycle progression. SF3B1 phosphorylation peaks at G2/M in a CDK1-dependent manner, and then decreases due to PP2A and PP1 phosphatase activities as the cell progresses through G1/S. SF3B1 in its unphosphorylated state allows the identification of short exons flanked by long introns by binding to the exons' nucleosome. SF3B1 binding to nucleosomes allow for alternative splicing of cell cycle genes.

381

382 **References**

- 383 1. Malumbres, M. (2014) Cyclin-dependent kinases. *Genome Biol* 15 (6), 122.
- 384 2. Murray, A.W. (2004) Recycling the cell cycle: cyclins revisited. *Cell* 116 (2), 221-34.
- 385 3. Ma, Y. et al. (2015) How the cell cycle impacts chromatin architecture and influences cell
386 fate. *Front Genet* 6, 19.
- 387 4. Chen, S. et al. (2010) Cyclin-dependent kinases regulate epigenetic gene silencing through
388 phosphorylation of EZH2. *Nat Cell Biol* 12 (11), 1108-14.
- 389 5. Giet, R. and Glover, D.M. (2001) Drosophila aurora B kinase is required for histone H3
390 phosphorylation and condensin recruitment during chromosome condensation and to organize
391 the central spindle during cytokinesis. *J Cell Biol* 152 (4), 669-82.
- 392 6. Wei, Y. et al. (1998) Phosphorylation of histone H3 at serine 10 is correlated with
393 chromosome condensation during mitosis and meiosis in *Tetrahymena*.
394 *Proceedings of the National Academy of Sciences* 95 (13), 7480-7484.
- 395 7. Dynlacht, B.D. (1997) Regulation of transcription by proteins that control the cell cycle.
396 *Nature* 389 (6647), 149-52.
- 397 8. Dominguez, D. et al. (2016) A high-resolution transcriptome map of cell cycle reveals
398 novel connections between periodic genes and cancer. *Cell Res* 26 (8), 946-62.
- 399 9. Whitfield, M.L. et al. (2002) Identification of genes periodically expressed in the human
400 cell cycle and their expression in tumors. *Molecular biology of the cell* 13 (6), 1977-2000.
- 401 10. Liu, Y. et al. (2017) Transcriptional landscape of the human cell cycle. *Proc Natl Acad*
402 *Sci U S A* 114 (13), 3473-3478.
- 403 11. Blencowe, B.J. (2003) Splicing regulation: the cell cycle connection. *Curr Biol* 13 (4),
404 R149-51.
- 405 12. Grzybowska, E.A. (2012) Human intronless genes: functional groups, associated
406 diseases, evolution, and mRNA processing in absence of splicing. *Biochem Biophys Res*
407 *Commun* 424 (1), 1-6.
- 408 13. Pena, V. et al. (2008) Structure and function of an RNase H domain at the heart of the
409 spliceosome. *EMBO J* 27 (21), 2929-40.
- 410 14. Matera, A.G. and Wang, Z. (2014) A day in the life of the spliceosome. *Nat Rev Mol Cell*
411 *Biol* 15 (2), 108-21.
- 412 15. Lee, Y. and Rio, D.C. (2015) Mechanisms and Regulation of Alternative Pre-mRNA
413 Splicing. *Annu Rev Biochem* 84, 291-323.

16. Wahl, M.C. et al. (2009) The spliceosome: design principles of a dynamic RNP machine. *Cell* 136 (4), 701-18.
17. Pan, Q. et al. (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. *Nat Genet* 40 (12), 1413-5.
18. Wang, E.T. et al. (2008) Alternative isoform regulation in human tissue transcriptomes. *Nature* 456 (7221), 470-6.
19. Fu, X.D. and Ares, M., Jr. (2014) Context-dependent control of alternative splicing by RNA-binding proteins. *Nat Rev Genet* 15 (10), 689-701.
20. Graveley, B.R. (2001) Alternative splicing: increasing diversity in the proteomic world. *Trends Genet* 17 (2), 100-7.
21. Black, D.L. (2003) Mechanisms of alternative pre-messenger RNA splicing. *Annu Rev Biochem* 72, 291-336.
22. Ge, Y. and Porse, B.T. (2014) The functional consequences of intron retention: alternative splicing coupled to NMD as a regulator of gene expression. *Bioessays* 36 (3), 236-43.
23. Wang, Z. and Burge, C.B. (2008) Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. *RNA* 14 (5), 802-13.
24. Long, J.C. and Cáceres, J.F. (2009) The SR protein family of splicing factors: master regulators of gene expression. *Biochem J* 417 (1), 15-27.
25. Krecic, A.M. and Swanson, M.S. (1999) hnRNP complexes: composition, structure, and function. *Curr Opin Cell Biol* 11 (3), 363-71.
26. Dominguez, D. et al. (2016) An extensive program of periodic alternative splicing linked to cell cycle progression. *Elife* 5, e10288.
27. Hwang, L.H. and Murray, A.W. (1997) A novel yeast screen for mitotic arrest mutants identifies DOC1, a new gene involved in cyclin proteolysis. *Mol Biol Cell* 8 (10), 1877-87.
28. Neumann, B. et al. (2010) Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. *Nature* 464 (7289), 721-7.
29. Lundgren, K. et al. (1996) A connection between pre-mRNA splicing and the cell cycle in fission yeast: *cdc28+* is allelic with *prp8+* and encodes an RNA-dependent ATPase/helicase. *Mol Biol Cell* 7 (7), 1083-94.
30. Shea, J.E. et al. (1994) The budding yeast U5 snRNP Prp8 is a highly conserved protein which links RNA splicing with cell cycle progression. *Nucleic Acids Res* 22 (25), 5555-64.
31. Takahashi, K. et al. (1994) Fission yeast minichromosome loss mutants mis cause lethal aneuploidy and replication abnormality. *Mol Biol Cell* 5 (10), 1145-58.

448 32. Nurse, P. et al. (1976) Genetic control of the cell division cycle in the fission yeast
449 *Schizosaccharomyces pombe*. *Mol Gen Genet* 146 (2), 167-78.

450 33. Ajuh, P. et al. (2000) Functional analysis of the human CDC5L complex and
451 identification of its components by mass spectrometry. *EMBO J* 19 (23), 6569-81.

452 34. Potashkin, J. et al. (1998) Cell-division-cycle defects associated with fission yeast pre-
453 mRNA splicing mutants. *Curr Genet* 34 (3), 153-63.

454 35. Salton, M. et al. (2015) Inhibition of vemurafenib-resistant melanoma by interference
455 with pre-mRNA splicing. *Nat Commun* 6, 7103.

456 36. Takehara, T. et al. (2001) Expression and role of Bcl-xL in human hepatocellular
457 carcinomas. *Hepatology* 34 (1), 55-61.

458 37. Bingle, C.D. et al. (2000) Exon skipping in Mcl-1 results in a bcl-2 homology domain 3
459 only gene product that promotes cell death. *J Biol Chem* 275 (29), 22136-46.

460 38. Todaro, M. et al. (2014) CD44v6 is a marker of constitutive and reprogrammed cancer
461 stem cells driving colon cancer metastasis. *Cell Stem Cell* 14 (3), 342-56.

462 39. Zheng, S. et al. (2014) Silent mutations make some noise. *Cell* 156 (6), 1129-31.

463 40. Kedzierska, H. and Piekliko-Witkowska, A. (2017) Splicing factors of SR and hnRNP
464 families as regulators of apoptosis in cancer. *Cancer Lett* 396, 53-65.

465 41. Tam, A.S. and Stirling, P.C. (2019) Splicing, genome stability and disease: splice like
466 your genome depends on it! *Curr Genet* 65 (4), 905-912.

467 42. Somma, M.P. et al. (2020) Moonlighting in Mitosis: Analysis of the Mitotic Functions of
468 Transcription and Splicing Factors. *Cells* 9 (6).

469 43. Galaktionov, K. and Beach, D. (1991) Specific activation of cdc25 tyrosine phosphatases
470 by B-type cyclins: evidence for multiple roles of mitotic cyclins. *Cell* 67 (6), 1181-94.

471 44. Malumbres, M. and Barbacid, M. (2005) Mammalian cyclin-dependent kinases. *Trends*
472 *Biochem Sci* 30 (11), 630-41.

473 45. Boutros, R. et al. (2007) CDC25 phosphatases in cancer cells: key players? Good targets?
474 *Nat Rev Cancer* 7 (7), 495-507.

475 46. Wegener, S. et al. (2000) Alternative splicing in the regulatory region of the human
476 phosphatases CDC25A and CDC25C. *Eur J Cell Biol* 79 (11), 810-5.

477 47. Forrest, A.R. et al. (1999) Multiple splicing variants of cdc25B regulate G2/M
478 progression. *Biochem Biophys Res Commun* 260 (2), 510-5.

479 48. Bureik, M. et al. (2000) An additional transcript of the cdc25C gene from A431 cells
480 encodes a functional protein. *Int J Oncol* 17 (6), 1251-8.

481 49. Ozen, M. and Ittmann, M. (2005) Increased expression and activity of CDC25C
482 phosphatase and an alternatively spliced variant in prostate cancer. *Clin Cancer Res* 11 (13),
483 4701-6.

484 50. Albert, H. et al. (2012) Genotoxic stress modulates CDC25C phosphatase alternative
485 splicing in human breast cancer cell lines. *Mol Oncol* 6 (5), 542-52.

486 51. Baldin, V. et al. (1997) Alternative splicing of the human CDC25B tyrosine phosphatase.
487 Possible implications for growth control? *Oncogene* 14 (20), 2485-95.

488 52. Kieffer, I. et al. (2007) Differential mitotic degradation of the CDC25B phosphatase
489 variants. *Oncogene* 26 (57), 7847-58.

490 53. Pacheco, T.R. et al. (2006) RNA interference knockdown of hU2AF35 impairs cell cycle
491 progression and modulates alternative splicing of Cdc25 transcripts. *Mol Biol Cell* 17 (10),
492 4187-99.

493 54. Andersen, D.S. and Tapon, N. (2008) Drosophila MFAP1 is required for pre-mRNA
494 processing and G2/M progression. *J Biol Chem* 283 (45), 31256-67.

495 55. Duncan, P.I. et al. (1997) In vivo regulation of alternative pre-mRNA splicing by the
496 Clk1 protein kinase. *Mol Cell Biol* 17 (10), 5996-6001.

497 56. Duncan, P.I. et al. (1995) Alternative splicing of STY, a nuclear dual specificity kinase. *J*
498 *Biol Chem* 270 (37), 21524-31.

499 57. Petersen, B.O. et al. (1999) Phosphorylation of mammalian CDC6 by cyclin A/CDK2
500 regulates its subcellular localization. *EMBO J* 18 (2), 396-410.

501 58. Ji, X. et al. (2018) PolyC-binding proteins enhance expression of the CDK2 cell cycle
502 regulatory protein via alternative splicing. *Nucleic Acids Res* 46 (4), 2030-2044.

503 59. Spector, D.L. et al. (1991) Associations between distinct pre-mRNA splicing components
504 and the cell nucleus. *EMBO J* 10 (11), 3467-81.

505 60. Gui, J.F. et al. (1994) Purification and characterization of a kinase specific for the serine-
506 and arginine-rich pre-mRNA splicing factors. *Proc Natl Acad Sci U S A* 91 (23), 10824-8.

507 61. Wang, H.Y. et al. (1998) SRPK2: a differentially expressed SR protein-specific kinase
508 involved in mediating the interaction and localization of pre-mRNA splicing factors in
509 mammalian cells. *J Cell Biol* 140 (4), 737-50.

510 62. Tripathi, K. and Parnaik, V.K. (2008) Differential dynamics of splicing factor SC35
511 during the cell cycle. *J Biosci* 33 (3), 345-54.

512 63. Hasenson, S.E. and Shav-Tal, Y. Speculating on the Roles of Nuclear Speckles: How
513 RNA-Protein Nuclear Assemblies Affect Gene Expression. *BioEssays* n/a (n/a), 2000104.

514 64. Gui, J.F. et al. (1994) A serine kinase regulates intracellular localization of splicing
515 factors in the cell cycle. *Nature* 369 (6482), 678-82.

516 65. Shin, C. and Manley, J.L. (2002) The SR protein SRp38 represses splicing in M phase
517 cells. *Cell* 111 (3), 407-17.

518 66. Feng, Y. et al. (2008) Phosphorylation switches the general splicing repressor SRp38 to a
519 sequence-specific activator. *Nat Struct Mol Biol* 15 (10), 1040-8.

520 67. Shi, Y. and Manley, J.L. (2007) A complex signaling pathway regulates SRp38
521 phosphorylation and pre-mRNA splicing in response to heat shock. *Mol Cell* 28 (1), 79-90.

522 68. Ben-David, Y. et al. (1991) A mammalian protein kinase with potential for
523 serine/threonine and tyrosine phosphorylation is related to cell cycle regulators. *EMBO J* 10
524 (2), 317-25.

525 69. Prasad, J. et al. (1999) The protein kinase Clk/Sty directly modulates SR protein activity:
526 both hyper- and hypophosphorylation inhibit splicing. *Mol Cell Biol* 19 (10), 6991-7000.

527 70. Colwill, K. et al. (1996) The Clk/Sty protein kinase phosphorylates SR splicing factors
528 and regulates their intranuclear distribution. *EMBO J* 15 (2), 265-75.

529 71. Xiao, S.H. and Manley, J.L. (1998) Phosphorylation-dephosphorylation differentially
530 affects activities of splicing factor ASF/SF2. *EMBO J* 17 (21), 6359-67.

531 72. Xu, L. et al. (2018) Phosphorylation of serine/arginine-rich splicing factor 1 at tyrosine
532 19 promotes cell proliferation in pediatric acute lymphoblastic leukemia. *Cancer Sci* 109
533 (12), 3805-3815.

534 73. Li, X. et al. (2005) Loss of splicing factor ASF/SF2 induces G2 cell cycle arrest and
535 apoptosis, but inhibits internucleosomal DNA fragmentation. *Genes Dev* 19 (22), 2705-14.

536 74. Okamoto, Y. et al. (1998) cdc2 kinase-mediated phosphorylation of splicing factor
537 SF2/ASF. *Biochem Biophys Res Commun* 249 (3), 872-8.

538 75. Koizumi, J. et al. (1999) The subcellular localization of SF2/ASF is regulated by direct
539 interaction with SR protein kinases (SRPKs). *J Biol Chem* 274 (16), 11125-31.

540 76. Tsai, W.Y. et al. (1999) Cef1p is a component of the Prp19p-associated complex and
541 essential for pre-mRNA splicing. *J Biol Chem* 274 (14), 9455-62.

542 77. McDonald, W.H. et al. (1999) Myb-related fission yeast cdc5p is a component of a 40S
543 snRNP-containing complex and is essential for pre-mRNA splicing. *Mol Cell Biol* 19 (8),
544 5352-62.

545 78. Ohi, M.D. et al. (2002) Proteomics analysis reveals stable multiprotein complexes in both
546 fission and budding yeasts containing Myb-related Cdc5p/Cef1p, novel pre-mRNA splicing
547 factors, and snRNAs. *Mol Cell Biol* 22 (7), 2011-24.

548 79. Leonard, D. et al. (2003) hLodestar/HuF2 interacts with CDC5L and is involved in pre-
549 mRNA splicing. *Biochem Biophys Res Commun* 308 (4), 793-801.

550 80. Lleres, D. et al. (2010) Direct interaction between hnRNP-M and CDC5L/PLRG1
551 proteins affects alternative splice site choice. *EMBO Rep* 11 (6), 445-51.

552 81. Liu, L. et al. (2003) Distinct domains of human CDC5 direct its nuclear import and
553 association with the spliceosome. *Cell Biochem Biophys* 39 (2), 119-32.

554 82. Golsteyn, R.M. et al. (1994) Cell cycle analysis and chromosomal localization of human
555 Plk1, a putative homologue of the mitotic kinases *Drosophila* polo and *Saccharomyces*
556 *cerevisiae* Cdc5. *J Cell Sci* 107 (Pt 6), 1509-17.

557 83. Burns, C.G. et al. (1999) Evidence that Myb-related CDC5 proteins are required for pre-
558 mRNA splicing. *Proc Natl Acad Sci U S A* 96 (24), 13789-94.

559 84. Ajuh, P. et al. (2001) A direct interaction between the carboxyl-terminal region of
560 CDC5L and the WD40 domain of PLRG1 is essential for pre-mRNA splicing. *J Biol Chem*
561 276 (45), 42370-81.

562 85. Bernstein, H.S. and Coughlin, S.R. (1997) *Pombe* Cdc5-related protein. A putative
563 human transcription factor implicated in mitogen-activated signaling. *J Biol Chem* 272 (9),
564 5833-7.

565 86. Graub, R. et al. (2008) Cell cycle-dependent phosphorylation of human CDC5 regulates
566 RNA processing. *Cell Cycle* 7 (12), 1795-803.

567 87. Boudrez, A. et al. (2000) NIPP1-mediated interaction of protein phosphatase-1 with
568 CDC5L, a regulator of pre-mRNA splicing and mitotic entry. *J Biol Chem* 275 (33), 25411-7.

569 88. Huang, R. et al. (2017) Prp19 Arrests Cell Cycle via Cdc5L in Hepatocellular Carcinoma
570 Cells. *Int J Mol Sci* 18 (4).

571 89. Mu, R. et al. (2014) Depletion of pre-mRNA splicing factor Cdc5L inhibits mitotic
572 progression and triggers mitotic catastrophe. *Cell Death Dis* 5, e1151.

573 90. Williams, S.D. et al. (2006) Adenoviral delivery of human CDC5 promotes G2/M
574 progression and cell division in neonatal ventricular cardiomyocytes. *Gene Ther* 13 (10),
575 837-43.

576 91. Burns, C.G. et al. (2002) Removal of a single alpha-tubulin gene intron suppresses cell
577 cycle arrest phenotypes of splicing factor mutations in *Saccharomyces cerevisiae*. *Mol Cell*
578 *Biol* 22 (3), 801-15.

579 92. Zhang, N. et al. (2009) Cdc5L interacts with ATR and is required for the S-phase cell-
580 cycle checkpoint. *EMBO Rep* 10 (9), 1029-35.

581 93. Kong, X.X. et al. (2016) HBx-induced MiR-1269b in NF-kappaB dependent manner
582 upregulates cell division cycle 40 homolog (CDC40) to promote proliferation and migration
583 in hepatoma cells. *J Transl Med* 14 (1), 189.

584 94. Ben Yehuda, S. et al. (1998) Identification and functional analysis of hPRP17, the human
585 homologue of the PRP17/CDC40 yeast gene involved in splicing and cell cycle control. *RNA*
586 4 (10), 1304-12.

587 95. Ben-Yehuda, S. et al. (2000) Extensive genetic interactions between PRP8 and
588 PRP17/CDC40, two yeast genes involved in pre-mRNA splicing and cell cycle progression.
589 *Genetics* 154 (1), 61-71.

590 96. Vaisman, N. et al. (1995) The role of *Saccharomyces cerevisiae* Cdc40p in DNA
591 replication and mitotic spindle formation and/or maintenance. *Mol Gen Genet* 247 (2), 123-
592 36.

593 97. Boger-Nadjar, E. et al. (1998) Efficient initiation of S-phase in yeast requires Cdc40p, a
594 protein involved in pre-mRNA splicing. *Mol Gen Genet* 260 (2-3), 232-41.

595 98. Chawla, G. et al. (2003) Dependence of pre-mRNA introns on PRP17, a non-essential
596 splicing factor: implications for efficient progression through cell cycle transitions. *Nucleic*
597 *Acids Res* 31 (9), 2333-43.

598 99. Dahan, O. and Kupiec, M. (2004) The *Saccharomyces cerevisiae* gene CDC40/PRP17
599 controls cell cycle progression through splicing of the ANC1 gene. *Nucleic Acids Res* 32 (8),
600 2529-40.

601 100. Horiuchi, K. et al. (2006) Wilms' tumor 1-associating protein regulates G2/M transition
602 through stabilization of cyclin A2 mRNA. *Proc Natl Acad Sci U S A* 103 (46), 17278-83.

603 101. Horiuchi, K. et al. (2013) Identification of Wilms' tumor 1-associating protein complex
604 and its role in alternative splicing and the cell cycle. *J Biol Chem* 288 (46), 33292-302.

605 102. Vohhodina, J. et al. (2017) The RNA processing factors THRAP3 and BCLAF1
606 promote the DNA damage response through selective mRNA splicing and nuclear export.
607 *Nucleic Acids Res* 45 (22), 12816-12833.

608 103. Suvorova, E.S. et al. (2013) Discovery of a splicing regulator required for cell cycle
609 progression. *PLoS Genet* 9 (2), e1003305.

610 104. Luco, R.F. et al. (2011) Epigenetics in alternative pre-mRNA splicing. *Cell* 144 (1), 16-
611 26.

612 105. Schwartz, S. et al. (2009) Chromatin organization marks exon-intron structure. *Nat*
613 *Struct Mol Biol* 16 (9), 990-5.

106. Andersson, R. et al. (2009) Nucleosomes are well positioned in exons and carry characteristic histone modifications. *Genome Res* 19 (10), 1732-41.
107. Zhou, H.L. et al. (2014) Regulation of alternative splicing by local histone modifications: potential roles for RNA-guided mechanisms. *Nucleic Acids Res* 42 (2), 701-13.
108. Xu, Y. et al. (2018) Alternative splicing links histone modifications to stem cell fate decision. *Genome Biol* 19 (1), 133.
109. Baker, M. et al. (2020) KDM3A regulates alternative splicing of cell-cycle genes following DNA damage. *bioRxiv*, 2020.02.26.965970.
110. Kaida, D. et al. (2007) Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. *Nat Chem Biol* 3 (9), 576-83.
111. Corrionero, A. et al. (2011) Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. *Genes Dev* 25 (5), 445-59.
112. MacMillan, A.M. et al. (1994) Dynamic association of proteins with the pre-mRNA branch region. *Genes Dev* 8 (24), 3008-20.
113. Kfir, N. et al. (2015) SF3B1 association with chromatin determines splicing outcomes. *Cell Rep* 11 (4), 618-29.
114. Wang, C. et al. (1998) Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. *Genes Dev* 12 (10), 1409-14.
115. de Graaf, K. et al. (2006) The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site. *BMC Biochem* 7, 7.
116. Bessonov, S. et al. (2010) Characterization of purified human Bact spliceosomal complexes reveals compositional and morphological changes during spliceosome activation and first step catalysis. *RNA* 16 (12), 2384-403.
117. Murthy, T. et al. (2018) Cyclin-dependent kinase 1 (CDK1) and CDK2 have opposing roles in regulating interactions of splicing factor 3B1 with chromatin. *J Biol Chem* 293 (26), 10220-10234.
118. Quesada, V. et al. (2011) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. *Nat Genet* 44 (1), 47-52.
119. Patnaik, M.M. et al. (2012) SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. *Blood* 119 (2), 569-72.
120. Furney, S.J. et al. (2013) SF3B1 mutations are associated with alternative splicing in uveal melanoma. *Cancer Discov* 3 (10), 1122-1129.

648 121. Maguire, S.L. et al. (2015) SF3B1 mutations constitute a novel therapeutic target in
649 breast cancer. *J Pathol* 235 (4), 571-80.

650 122. Tang, Q. et al. (2016) SF3B1/Hsh155 HEAT motif mutations affect interaction with the
651 spliceosomal ATPase Prp5, resulting in altered branch site selectivity in pre-mRNA splicing.
652 *Genes Dev* 30 (24), 2710-2723.

653 123. Qiu, J. et al. (2016) Distinct splicing signatures affect converged pathways in
654 myelodysplastic syndrome patients carrying mutations in different splicing regulators. *RNA*
655 22 (10), 1535-49.

656 124. Darman, R.B. et al. (2015) Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic
657 3' Splice Site Selection through Use of a Different Branch Point. *Cell Rep* 13 (5), 1033-45.

658 125. DeBoever, C. et al. (2015) Transcriptome sequencing reveals potential mechanism of
659 cryptic 3' splice site selection in SF3B1-mutated cancers. *PLoS Comput Biol* 11 (3),
660 e1004105.

661 126. Kesarwani, A.K. et al. (2017) Cancer-associated SF3B1 mutants recognize otherwise
662 inaccessible cryptic 3' splice sites within RNA secondary structures. *Oncogene* 36 (8), 1123-
663 1133.

664 127. Liu, Z. et al. (2020) Mutations in the RNA Splicing Factor SF3B1 Promote
665 Tumorigenesis through MYC Stabilization. *Cancer Discov* 10 (6), 806-821.

666 128. Gentien, D. et al. (2014) A common alternative splicing signature is associated with
667 SF3B1 mutations in malignancies from different cell lineages. *Leukemia* 28 (6), 1355-7.

668 129. Dolatshad, H. et al. (2015) Disruption of SF3B1 results in deregulated expression and
669 splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and
670 progenitor cells. *Leukemia* 29 (5), 1092-103.

671 130. Huang, Y. et al. (2018) SF3B1 deficiency impairs human erythropoiesis via activation of
672 p53 pathway: implications for understanding of ineffective erythropoiesis in MDS. *J Hematol*
673 *Oncol* 11 (1), 19.

674 131. De La Garza, A. et al. (2019) The splicing factor Sf3b1 regulates erythroid maturation
675 and proliferation via TGFbeta signaling in zebrafish. *Blood Adv* 3 (14), 2093-2104.

676 132. Salton, M. and Misteli, T. (2016) Small Molecule Modulators of Pre-mRNA Splicing in
677 Cancer Therapy. *Trends Mol Med* 22 (1), 28-37.

678 133. Zhang, L. et al. (2020) Knockdown of SF3B1 inhibits cell proliferation, invasion and
679 migration triggering apoptosis in breast cancer via aberrant splicing. *Breast Cancer* 27 (3),
680 464-476.

134. Zhang, Q. et al. (2019) Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells. *Artif Cells Nanomed Biotechnol* 47 (1), 1273-1280.
135. Kotake, Y. et al. (2007) Splicing factor SF3b as a target of the antitumor natural product pladienolide. *Nat Chem Biol* 3 (9), 570-5.
136. Hasegawa, M. et al. (2011) Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product. *ACS Chem Biol* 6 (3), 229-33.
137. Effenberger, K.A. et al. (2017) Modulating splicing with small molecular inhibitors of the spliceosome. *Wiley Interdiscip Rev RNA* 8 (2).
138. Triegeer, K.A. et al. (2020) Splice Modulation Synergizes Cell Cycle Inhibition. *ACS Chem Biol* 15 (3), 669-674.
139. Jorge, J. et al. (2020) Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines. *Invest New Drugs* 38 (2), 369-377.
140. Vanzyl, E.J. et al. (2018) Flow cytometric analysis identifies changes in S and M phases as novel cell cycle alterations induced by the splicing inhibitor isoginkgetin. *PLoS One* 13 (1), e0191178.
141. Convertini, P. et al. (2014) Sudemycin E influences alternative splicing and changes chromatin modifications. *Nucleic Acids Res* 42 (8), 4947-61.
142. Teng, T. et al. (2017) Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex. *Nat Commun* 8, 15522.
143. Yokoi, A. et al. (2011) Biological validation that SF3b is a target of the antitumor macrolide pladienolide. *FEBS J* 278 (24), 4870-80.

Glossary

Chromosomal passenger complex (CPC): This functions at the centromere to ensure correct chromosome alignment and segregation.

Enhancer RNA: short non-coding RNA molecules (50-2000 nucleotides) transcribed from the DNA sequence of enhancer regions which have a role in transcriptional regulation.

Histone demethylase: An enzyme that removes methyl (CH₃-) groups from histones that is important in epigenetic modification mechanisms. Histone demethylases alter transcriptional regulation of the genome by controlling the methylation levels that occur on histones and so regulate the chromatin state at specific gene loci within organisms.

714 **Nuclear speckles:** nuclear domains enriched in pre-mRNA splicing factors, located in the
715 interchromatin regions of the nucleoplasm of mammalian cells.

716 **Nucleosomes:** the basic structural unit of DNA packaging in eukaryotes consisting of a
717 segment of DNA wound around eight histone proteins. It is the fundamental subunit of
718 chromatin.

719 **R loop:** a three-stranded nucleic acid structure, composed of a DNA:RNA hybrid and the
720 associated non-template single-stranded DNA, formed in a variety of circumstances. The
721 presence of R-loops can inhibit transcription and R-loop formation appears to be associated
722 with “open” chromatin, characteristic of actively transcribed regions.

723 **Small nuclear RNA (snRNA):** a class of small RNA molecules of around 150 nucleotides
724 that are found within the splicing speckles and Cajal bodies of the cell nucleus in eukaryotic
725 cells. Their primary function is in the processing of pre-messenger RNA (hnRNA) in the
726 nucleus.

727 **Unstructured domains:** also called auxiliary domains, these are proline-, glycine- or acid-
728 rich. These domains are speculated to provide the specificity of the RNA binding domain in
729 the hnRNP protein family. This is facilitated by the 3D structure of the protein around the
730 RNA binding domains which fine-tunes the RNA–protein interaction.

731